Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 4/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231644 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL702875 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL2231754 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL18148230 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL2232446 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL2233750 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL2232477 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL701835 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL703959 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG | |
| SCHEMBL702796 | 1.00 | LPAR1 (0.52) | LPAR1LPAR3TLR2GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464957-B2 | Oxidized lipids and methods of use thereof | VASCULAR BIOGENICS LTD. (IL) | 2019-11-05 | — | — | US | disclosed |
| US-9968622-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2018-05-15 | — | — | US | disclosed |
| US-20170369516-A1 | Oxidized Lipids and Methods of Use Thereof | VASCULAR BIOGENICS LTD. (IL) | 2017-12-28 | — | — | US | disclosed |
| US-9771385-B2 | Oxidized lipids | VASCULAR BIOGENICS LTD. (IL) | 2017-09-26 | — | — | US | disclosed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| US-20160304544-A1 | Oxidized Lipids and Methods of Use Thereof | VASCULAR BIOGENICS LTD. (IL) | 2016-10-20 | — | — | US | disclosed |
| EP-2125838-B1 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD (IL) | 2016-05-11 | — | — | EP | disclosed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-9006217-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-04-14 | — | — | US | disclosed |
| US-20130237720-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-09-12 | — | — | US | disclosed |
| US-20130190523-A1 | Process for the Preparation of Oxidized Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-07-25 | — | — | US | disclosed |
| US-20130158283-A1 | Process for the Preparation of Oxidized Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-06-20 | — | — | US | disclosed |
| US-20130079540-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| EP-2522672-A1 | Oxidized phospholipids | Vascular Biogenics Ltd. (IL) | 2012-11-14 | — | — | EP | disclosed |
| US-20120130108-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2012-05-24 | — | — | US | disclosed |
| US-8124800-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2012-02-28 | — | — | US | disclosed |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2010-12-16 | — | — | US | disclosed |
| US-7807847-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2010-10-05 | — | — | US | disclosed |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369516-A1 | Oxidized Lipids and Methods of Use Thereof | LPO, LIPA, GPX4 | LPAR1 304/4885LPAR3 282/4885TLR2 932/4885 |
| US-20130190523-A1 | Process for the Preparation of Oxidized Phospholipids | PHOSPHO1, SGMS1, SGMS2 | LPAR1 203/4885LPAR3 310/4885TLR2 4044/4885 |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | PHOSPHO1, SGMS1, SGMS2 | LPAR1 199/4885LPAR3 323/4885TLR2 3800/4885 |
| US-10464957-B2 | Oxidized lipids and methods of use thereof | LPO, LIPA, GPX4 | LPAR1 304/4885LPAR3 282/4885TLR2 932/4885 |
| US-20130079540-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | LPAR1 77/4885LPAR3 114/4885TLR2 3397/4885 |
| US-20150216882-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | LPAR1 71/4885LPAR3 126/4885TLR2 3326/4885 |
| US-20130158283-A1 | Process for the Preparation of Oxidized Phospholipids | PHOSPHO1, SGMS1, SGMS2 | LPAR1 199/4885LPAR3 323/4885TLR2 3800/4885 |
| US-20170246197-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | LPAR1 71/4885LPAR3 126/4885TLR2 3326/4885 |
| US-20120130108-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | PHOSPHO1, SGMS1, SGMS2 | LPAR1 199/4885LPAR3 323/4885TLR2 3800/4885 |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | PHOSPHO1, SGMS1, SGMS2 | LPAR1 199/4885LPAR3 323/4885TLR2 3800/4885 |
| US-20160304544-A1 | Oxidized Lipids and Methods of Use Thereof | LPO, LIPA, GPX4 | LPAR1 304/4885LPAR3 282/4885TLR2 932/4885 |
| US-20130237720-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | LPAR1 71/4885LPAR3 126/4885TLR2 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.